STREAMLINE®SURGICAL SYSTEM Compared to iStent Inject W® in Patients With Open-Angle Glaucoma
VENICE
A Prospective, Randomized, Multi-center Evaluation of the Safety and Effectiveness of the STREAMLINE®SURGICAL SYSTEM Compared to iStent Inject W® in Patients With Open-Angle Glaucoma
1 other identifier
interventional
150
3 countries
20
Brief Summary
A study of the Streamline Surgical System versus competitor
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Feb 2022
Longer than P75 for not_applicable
20 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 29, 2021
CompletedStudy Start
First participant enrolled
February 9, 2022
CompletedFirst Posted
Study publicly available on registry
March 15, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
June 30, 2026
November 12, 2024
April 1, 2024
4.4 years
December 29, 2021
November 7, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Change in mean unmedicated diurnal Intraocular Pressure (IOP)
Change in mean unmedicated diurnal Intraocular Pressure (IOP) over time
24 months
Study Arms (2)
Streamline Surgical System
OTHERStreamline Surgical System procedure administered
iStent Inject W
ACTIVE COMPARATORiStent Inject W implanted
Interventions
Completion of the Streamline Surgical System procedure
Eligibility Criteria
You may qualify if:
- Diagnosis of Mild to Moderate Primary Open Angle Glaucomma
You may not qualify if:
- Other types of glaucoma including but not limited to: Normal tension glaucoma, pseudoexfoliative glaucoma, narrow angle glaucoma, traumatic, congenital, malignant, uveitic or neovascular glaucoma. Ocular hypertension.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (20)
Vold Vision
Fayetteville, Arkansas, 72704, United States
Visionary Research Institute
Newport Beach, California, 92663, United States
Wolstan and Goldberg Eye Associates
Torrance, California, 90505, United States
University of Colorado
Aurora, Colorado, 80045, United States
Ocala Eye
Ocala, Florida, 34474, United States
Georgia Eye Partners
Atlanta, Georgia, 30342, United States
The Eye Institute
Louisville, Kentucky, 40206, United States
Ophthalmology Associates
St Louis, Missouri, 63131, United States
Eye Associates of North New Jersey
Dover, New Jersey, 07927, United States
Eye Associates Surgical Center
Vineland, New Jersey, 08361, United States
Ross Eye Institute
Orchard Park, New York, 14127, United States
Black Hills Regional Eye Institute
Rapid City, South Dakota, 57701, United States
University Eye Specialists
Maryville, Tennessee, 37003, United States
Ophthalmology Associates
Fort Worth, Texas, 76102, United States
Berkely Eye Center
Houston, Texas, 77027, United States
R & R Eye Research
San Antonio, Texas, 78229, United States
Piedmont Eye Center
Lynchburg, Virginia, 24052, United States
Eye Centers of Racine and Kenosha
Racine, Wisconsin, 53405, United States
Clinica 20/20
San José, 10108, Costa Rica
Clinica Laser y Ultrasonido Ocular
Puebla City, 72530, Mexico
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Elysia Ison, OD
New World Medical, Inc.
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 29, 2021
First Posted
March 15, 2022
Study Start
February 9, 2022
Primary Completion (Estimated)
June 30, 2026
Study Completion (Estimated)
June 30, 2026
Last Updated
November 12, 2024
Record last verified: 2024-04
Data Sharing
- IPD Sharing
- Will not share